The effect of cimetidine on parathyroid function and histopathology in primary hyperparathyroidism. 1987

F C Sotsiou, and P N Singhellakis, and A D Nikou, and A D Pappas, and C Vambouka, and N G Sklivagou, and D G Ikkos

Recent evidence suggests that cimetidine given pre-operatively in primary hyperparathyroidism (1 degree HPT) might cause structural changes in parathyroid glands, while its suppressive effects on the disease are disputable. To determine these possible changes we studied 38 patients with 1 degree HPT who underwent parathyroidectomy. In 14 of these (group I) cimetidine was given pre-operatively (1000 mg orally daily for 4 weeks). The remaining 24 patients (group II) did not take any drug. Parathyroid function was estimated by nephrogenous cAMP (NcAMP) and serum immunoreactive parathyroid hormone (iPTH) measurements. Histological examination of the parathyroids was made by conventional techniques. In group I at the end of cimetidine treatment, the only change observed was a small but significant (p less than 0.05) decrease of plasma calcium (-0.77 mg/dl). Histologically, the glands of group I--compared with those of group II--showed the following findings: increased gland mass: mean increase 1050 mg (adenomas) and 700 mg (hyperplasias); central oedema in all the cases of group I only; increased (about 50 per cent) cellular size and intranuclear 'inclusions' in 10 out of 14 cases of group I only. It is concluded that treatment with cimetidine in 1 degree HPT is followed by histopathologic alterations leading to increased size of the diseased parathyroids.

UI MeSH Term Description Entries
D006961 Hyperparathyroidism A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
D006965 Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells. Hyperplasias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009929 Organ Size The measurement of an organ in volume, mass, or heaviness. Organ Volume,Organ Weight,Size, Organ,Weight, Organ
D010280 Parathyroid Glands Two pairs of small oval-shaped glands located in the front and the base of the NECK and adjacent to the two lobes of THYROID GLAND. They secrete PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body. Gland, Parathyroid,Glands, Parathyroid,Parathyroid Gland
D010282 Parathyroid Neoplasms Tumors or cancer of the PARATHYROID GLANDS. Cancer of Parathyroid,Parathyroid Cancer,Cancer of the Parathyroid,Neoplasms, Parathyroid,Parathyroid Adenoma,Parathyroid Carcinoma,Adenoma, Parathyroid,Adenomas, Parathyroid,Cancer, Parathyroid,Cancers, Parathyroid,Carcinoma, Parathyroid,Carcinomas, Parathyroid,Neoplasm, Parathyroid,Parathyroid Adenomas,Parathyroid Cancers,Parathyroid Carcinomas,Parathyroid Neoplasm
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002927 Cimetidine A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Altramet,Biomet,Biomet400,Cimetidine HCl,Cimetidine Hydrochloride,Eureceptor,Histodil,N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine,SK&F-92334,SKF-92334,Tagamet,HCl, Cimetidine,Hydrochloride, Cimetidine,SK&F 92334,SK&F92334,SKF 92334,SKF92334
D005260 Female Females

Related Publications

F C Sotsiou, and P N Singhellakis, and A D Nikou, and A D Pappas, and C Vambouka, and N G Sklivagou, and D G Ikkos
March 1980, Lancet (London, England),
F C Sotsiou, and P N Singhellakis, and A D Nikou, and A D Pappas, and C Vambouka, and N G Sklivagou, and D G Ikkos
March 1984, Presse medicale (Paris, France : 1983),
F C Sotsiou, and P N Singhellakis, and A D Nikou, and A D Pappas, and C Vambouka, and N G Sklivagou, and D G Ikkos
December 1983, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
F C Sotsiou, and P N Singhellakis, and A D Nikou, and A D Pappas, and C Vambouka, and N G Sklivagou, and D G Ikkos
January 1963, The Scientific basis of medicine annual reviews,
F C Sotsiou, and P N Singhellakis, and A D Nikou, and A D Pappas, and C Vambouka, and N G Sklivagou, and D G Ikkos
August 1988, World journal of surgery,
F C Sotsiou, and P N Singhellakis, and A D Nikou, and A D Pappas, and C Vambouka, and N G Sklivagou, and D G Ikkos
November 1982, British journal of clinical pharmacology,
F C Sotsiou, and P N Singhellakis, and A D Nikou, and A D Pappas, and C Vambouka, and N G Sklivagou, and D G Ikkos
June 1952, El Dia medico,
F C Sotsiou, and P N Singhellakis, and A D Nikou, and A D Pappas, and C Vambouka, and N G Sklivagou, and D G Ikkos
December 1983, Journal of endocrinological investigation,
F C Sotsiou, and P N Singhellakis, and A D Nikou, and A D Pappas, and C Vambouka, and N G Sklivagou, and D G Ikkos
November 1984, Lancet (London, England),
F C Sotsiou, and P N Singhellakis, and A D Nikou, and A D Pappas, and C Vambouka, and N G Sklivagou, and D G Ikkos
July 1981, La Clinica terapeutica,
Copied contents to your clipboard!